# Myosana Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/myosana-therapeutics

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.myosanatherapeutics.com
- Total disclosed funding: $6.4M
- Latest round: Seed (Nov 22, 2022)
- Investors on record: 3

## About

Myosana Therapeutics, Inc., based in Seattle, US, is focused on developing a non-viral gene therapy platform to treat neuromuscular and cardiac genetic diseases, particularly Duchenne muscular dystrophy and X-linked myotubular myopathy.Myosana Therapeutics, founded in 2018 in Seattle, US, specializes in innovative gene therapies. The company has secured funding through three deals, with its most recent being a Seed round in November 2022, raising USD 6.4 mn from investors including CureDuchenne Ventures and the Muscular Dystrophy Association. The current CEO is Matthew Lumley, supported by Nick Whitehead and Stan Froehner, who have a background in founding other ventures in biotechnology and healthcare.Myosana Therapeutics specializes in developing a targeted non-viral gene therapy platform aimed at addressing neuromuscular and cardiac genetic diseases. Their core product offerings include innovative gene therapies designed to treat conditions such as Duchenne muscular dystrophy (DMD) and X-linked myotubular myopathy (MTM). The Myosana platform is engineered to overcome the inherent limitations of viral delivery methods, allowing for a broader range of genetic diseases to be treated. The end users of these therapies are primarily patients suffering from severe genetic disorders characterized by muscle degeneration and cardiac complications. Myosana’s solutions are currently positioned within the healthcare markets of North America and Europe, focusing on hospitals, specialized clinics, and research institutions that manage patients with these genetic conditions.Myosana Therapeutics has successfully raised USD 6.4 mn in funding to support its research and development endeavors, although specific revenue figures are not disclosed. The company partners with organizations like the Muscular Dystrophy Association and Parent Project Muscular Dystrophy, which provide funding for advancing their non-viral gene therapy platform. Their business model involves collaborations with healthcare providers and research institutions for the development and potential commercialization of their therapies, adopting a B2B approach for clinical trials and distribution agreements.In November 2022, Myosana Therapeutics raised USD 6.4 mn in Seed funding to support the development of its non-viral gene therapy delivery platform. The company is focused on expanding its product pipeline, aiming to enhance its offerings for treating genetic disorders. Plans for geographic expansion include targeting markets in Europe by the end of 2024, as they develop strategic partnerships to facilitate entry into these regions.

## Funding rounds

- Seed, Nov 22, 2022, $6.4M — Muscular Dystrophy Association, Parent Project Muscular Dystrophy, CureDuchenne Ventures

## Investors

- Muscular Dystrophy Association — Seed
- Parent Project Muscular Dystrophy — Seed
- CureDuchenne Ventures (https://capitalatlas.ai/funds/cureduchenne-ventures) — Seed